Purpose <p>ASP9801, an oncolytic virus encoding interleukin-7 and interleukin-12, was assessed for safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced solid tumors in a Phase 1 study.</p> Methods <p>The study comprised Part 1 ASP9801 monotherapy dose escalation and Part 2 dose expansion with ASP9801 monotherapy or plus pembrolizumab. Each part was divided into Groups A (ASP9801 injection into…
Phase 1 open-label study of ASP9801, an oncolytic virus, in patients with advanced or metastatic solid tumors
Journal for ImmunoTherapy of Cancer | | Villano, J. L., Luke, J. J., Julian, R., Fountzilas, C., Patel, M. R., Chisamore, M. J., Bhattacharya, P., Takeshita, S., Soukharev, S., Yamada, S., Zhang, L., Wentzel, K. P.
Topics: immunotherapy, clinical-trials, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer